Video

CNS and Dose-Reduction Events After Abiraterone/Prednisone in mCRPC

Author(s):

Ajay S. Behl, PhD
Conference|ASCO Annual Meeting

Ajay S. Behl, PhD, Janssen Pharmaceuticals, discusses a study examining the central nervous system (CNS) and dose-reduction events in patients with prostate cancer following treatment with abiraterone acetate (Zytiga) plus prednisone.

Ajay S. Behl, PhD, Janssen Pharmaceuticals, discusses a study examining the central nervous system (CNS) and dose-reduction events in patients with metastatic castration-resistant prostate cancer (mCRPC) following treatment with abiraterone acetate (Zytiga) plus prednisone.

These events were observed in comparison with patients who were treated with enzalutamide (Xtandi), Behl explains. This study is part of a larger investigation that is seeking to understand the differences between oral therapies used to treat mCRPC, including abiraterone and enzalutamide.

Results showed that patients who were treated with enzalutamide experienced more CNS events and fatigue compared with patients in the abiraterone and prednisone arm, Behl says.

Related Videos
Julia Rotow, MD, clinical director, Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute; assistant professor, medicine, Harvard Medical School
Joshua K. Sabari, MD, assistant professor, Department of Medicine, New York University Grossman School of Medicine; director, High Reliability Organization Initiatives, Perlmutter Cancer Center
Alastair Thompson, BSc, MBChB, MD, FRCS
C. Ola Landgren, MD, PhD
Sara M. Tolaney, MD, MPH
Adam M. Brufsky, MD, PhD, FACP
Justin M. Watts, MD
Sara M. Tolaney, MD, MPH
Leah Backhus, MD, MPH, FACS, professor, University Medical Line, Cardiothoracic Surgery, co-director, Thoracic Surgery Clinical Research Program, associate program director, Thoracic Track, CT Surgery Residency Training Program, Thelma and Henry Doelger Professor of Cardiovascular Surgery, Stanford Medicine; chief, Thoracic Surgery, VA Palo Alto
Roy S. Herbst, MD, PhD, Ensign Professor of Medicine (Medical Oncology), professor, pharmacology, deputy director, Yale Cancer Center; chief, Medical Oncology, director, Center for Thoracic Cancers, Yale Cancer Center and Smilow Cancer Hospital; assistant dean, Translational Research, Yale School of Medicine
Related Content
Christian Behrenbruch PhD, MBA
July 24th 2024

FDA Accepts the New Drug Application for TLX007-CDx Kit in Prostate Cancer

Neeraj Agarwal, MD
July 17th 2023

FDA Approval Insights: Talazoparib Plus Enzalutamide in HRR Gene–Mutated mCRPC

Lynn M. Schuchter, MD, of Penn Medicine
July 16th 2024

ASCO 2024 Data Shake Up Standards and Shed Light on Biomarkers

Andrew J. Armstrong, MD, MSc
June 15th 2023

FDA Approval Insights: Olaparib Plus Abiraterone in BRCA-Mutated mCRPC

US FDA
July 8th 2024

FDA Grants Fast Track Designation to BNT324/DB-1311 in mCRPC

S. Lindsey Davis, MD, oncologist, University of Colorado Cancer Center; associate professor, medicine-medical oncology, University of Colorado Anschutz Medical Campus
July 5th 2024

The Role of mTOR/Aurora A Kinase Combination Therapy Requires Further Elucidation in Solid Tumors